Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

Imagem de Miniatura
Arquivos
art_VOS_Global_regional_and_national_incidence_prevalence_and_years_2017.PDF (23.72 MB)
Citações na Scopus
5247
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
VOS, Theo
ABAJOBIR, Amanuel Alemu
ABBAFATI, Cristiana
ABBAS, Kaja M.
ABATE, Kalkidan Hassen
ABD-ALLAH, Foad
ABDULLE, Abdishakur M.
ABEBO, Teshome Abuka
ABERA, Semaw Ferede
ABOYANS, Victor
Citação
LANCET, v.390, n.10100, p.1211-1259, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background As mortality rates decline, life expectancy increases, and populations age, non-fatal outcomes of diseases and injuries are becoming a larger component of the global burden of disease. The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016. Methods We estimated prevalence and incidence for 328 diseases and injuries and 2982 sequelae, their non-fatal consequences. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring consistency between incidence, prevalence, remission, and cause of death rates for each condition. For some causes, we used alternative modelling strategies if incidence or prevalence needed to be derived from other data. YLDs were estimated as the product of prevalence and a disability weight for all mutually exclusive sequelae, corrected for comorbidity and aggregated to cause level. We updated the Socio-demographic Index (SDI), a summary indicator of income per capita, years of schooling, and total fertility rate. GBD 2016 complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER). Findings Globally, low back pain, migraine, age-related and other hearing loss, iron-deficiency anaemia, and major depressive disorder were the five leading causes of YLDs in 2016, contributing 57.6 million (95% uncertainty interval [UI] 40.8-75.9 million [7.2%, 6.0-8.3]), 45.1 million (29.0-62.8 million [5.6%, 4.0-7.2]), 36.3 million (25.3-50.9 million [4.5%, 3.8-5.3]), 34.7 million (23.0-49.6 million [4.3%, 3.5-5.2]), and 34.1 million (23.5-46.0 million [4.2%, 3.2-5.3]) of total YLDs, respectively. Age-standardised rates of YLDs for all causes combined decreased between 1990 and 2016 by 2.7% (95% UI 2.3-3.1). Despite mostly stagnant age-standardised rates, the absolute number of YLDs from non-communicable diseases has been growing rapidly across all SDI quintiles, partly because of population growth, but also the ageing of populations. The largest absolute increases in total numbers of YLDs globally were between the ages of 40 and 69 years. Age-standardised YLD rates for all conditions combined were 10.4% (95% UI 9.0-11.8) higher in women than in men. Iron-deficiency anaemia, migraine, Alzheimer's disease and other dementias, major depressive disorder, anxiety, and all musculoskeletal disorders apart from gout were the main conditions contributing to higher YLD rates in women. Men had higher age-standardised rates of substance use disorders, diabetes, cardiovascular diseases, cancers, and all injuries apart from sexual violence. Globally, we noted much less geographical variation in disability than has been documented for premature mortality. In 2016, there was a less than two times difference in age-standardised YLD rates for all causes between the location with the lowest rate (China, 9201 YLDs per 100 000, 95% UI 6862-11943) and highest rate (Yemen, 14 774 YLDs per 100 000, 11 018-19 228). Interpretation The decrease in death rates since 1990 for most causes has not been matched by a similar decline in age-standardised YLD rates. For many large causes, YLD rates have either been stagnant or have increased for some causes, such as diabetes. As populations are ageing, and the prevalence of disabling disease generally increases steeply with age, health systems will face increasing demand for services that are generally costlier than the interventions that have led to declines in mortality in childhood or for the major causes of mortality in adults. Up-todate information about the trends of disease and how this varies between countries is essential to plan for an adequate health-system response.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/21820
Referências
  1. Afshin A, 2017, NEW ENGL J MED, V377, P13, DOI 10.1056/NEJMoa1614362
  2. Agency for Healthcare Research and Quality, US MED EXP PAN SURV
  3. Anand A., UNDERSTANDING DEPRES
  4. Banks JL, 2007, STROKE, V38, P1091, DOI 10.1161/01.STR.0000258355.23810.c6
  5. Barber RM, 2017, LANCET, V390, P231, DOI 10.1016/S0140-6736(17)30818-8
  6. Barry M, 2007, NEW ENGL J MED, V356, P2561, DOI 10.1056/NEJMp078089
  7. Brooker S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000779
  8. Burnham G, 2016, HUMAN COST WAR IRAQ
  9. Chavan BS, 2016, INDIAN J SOC PSYCHIA, V32, P261
  10. Dieleman JL, 2016, JAMA-J AM MED ASSOC, V316, P2627, DOI 10.1001/jama.2016.16885
  11. Flaxman AD, 2015, INTEGRATIVE METAREGR
  12. GBD Risk Factors Collaborators, 2016, LANCET, V390, P1345
  13. Ghosh A, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0445-8
  14. Hassan G, 2016, EPIDEMIOL PSYCH SCI, V25, P129, DOI 10.1017/S2045796016000044
  15. Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
  16. International Agency for Research on Cancer, 2017, GLOB 2012 EST CANC I
  17. Jackson T, 2016, ANESTH ANALG, V123, P739, DOI 10.1213/ANE.0000000000001389
  18. Jager KJ, 2017, NEPHROL DIAL TRANSPL, V32, P121, DOI 10.1093/ndt/gfw330
  19. Jensen ET, 2015, ANN EPIDEMIOL, V25, P519, DOI 10.1016/j.annepidem.2015.03.008
  20. Jin LJ, 2016, ORAL DIS, V22, P609, DOI 10.1111/odi.12428
  21. Kassebaum NJ, 2016, LANCET, V388, P1603, DOI 10.1016/S0140-6736(16)31460-X
  22. Kissoon N, 2016, JAMA PEDIATR, V170, P107, DOI 10.1001/jamapediatrics.2015.3241
  23. Kottke TE, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.120009
  24. Kwan GF, 2016, CIRCULATION, V133, P2561, DOI 10.1161/CIRCULATIONAHA.116.008731
  25. Lim SS, 2016, LANCET, V388, P1813, DOI 10.1016/S0140-6736(16)31467-2
  26. Limmathurotsakul D, 2016, NATURE MICROBIOLOGY
  27. McKee S., 2016, RETHINKING DEV HLTH
  28. McMichael AJ, 2006, LANCET, V367, P859, DOI 10.1016/S0140-6736(06)68079-3
  29. Mesfin YM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082235
  30. Ministry of Health ICF International Centers for Disease Control and Prevention U. S. Agency for International Development and WHO Uganda, 2012, UG AIDS IND SURV
  31. Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
  32. National AIDS and STI Control Programme (NASCOP), 2014, KEN AIDS IND SURV 20
  33. National Tuberculosis Institute [India], 1974, B WORLD HEALTH ORGAN, V51, P473
  34. Neethling I, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.31754
  35. Nino F., UN SUSTAINABLE DEV G
  36. Parker G, 2001, SOC PSYCH PSYCH EPID, V36, P287, DOI 10.1007/s001270170046
  37. Patel V, 2016, LANCET, V387, P1672, DOI 10.1016/S0140-6736(15)00390-6
  38. Patz JA, 2005, NATURE, V438, P310, DOI 10.1038/nature04188
  39. Phillips MR, 2009, LANCET, V373, P2041, DOI 10.1016/S0140-6736(09)60660-7
  40. Ramsey R, 2012, PUBLIC HEALTH NUTR, V15, P227, DOI 10.1017/S1368980011001996
  41. Rothberg MB, 2014, ANN INTERN MED, V160, P380, DOI 10.7326/M13-1419
  42. Spellberg B, 2013, NEW ENGL J MED, V368, P299, DOI 10.1056/NEJMp1215093
  43. Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
  44. Tsang A, 2008, J PAIN, V9, P883, DOI 10.1016/j.jpain.2008.05.005
  45. Tung W. C., 2015, HOME HLTH CARE MANAG, V27, P95, DOI [10.1177/1084822314547962, DOI 10.1177/1084822314547962]
  46. UNAIDS, 2016, GLOB AIDS UPD 2016
  47. Vallabhaneni S, 2016, INFECT DIS CLIN N AM, V30, P1, DOI 10.1016/j.idc.2015.10.004
  48. Vigo D, 2016, LANCET PSYCHIAT, V3, P171, DOI 10.1016/S2215-0366(15)00505-2
  49. Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6
  50. Wang HD, 2017, LANCET, V390, P1084, DOI 10.1016/S0140-6736(17)31833-0
  51. World Health Organization, 2014, COMP HDB WHO GUID PR
  52. WHO, 5 M EM COMM INT HLTH
  53. WHO, 2016, GLOB TUB REP 2016
  54. WHO, 2015, GUID MAN LAT TUB INF
  55. WHO, 2014, ANT RES GLOB REP SUR
  56. Yeom H, 2015, EPIDEMIOL HLTH, V37

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - LIM/23
Artigos e Materiais de Revistas Científicas - LIM/51
Carregar mais